Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
9.60
+0.26 (2.78%)
At close: Aug 25, 2026, 4:00 PM EDT
9.75
+0.15 (1.56%)
Pre-market: Aug 26, 2026, 4:00 AM EDT
Arvinas Employees
Arvinas had 246 employees as of December 31, 2025. The number of employees decreased by 184 or -42.79% compared to the previous year.
Employees
246
Change (1Y)
-184
Growth (1Y)
-42.79%
Revenue / Employee
$1,287,398
Profits / Employee
$37,805
Market Cap
627.71M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 246 | -184 | -42.79% |
| Dec 31, 2024 | 430 | -15 | -3.37% |
| Dec 31, 2023 | 445 | 30 | 7.23% |
| Dec 31, 2022 | 415 | 135 | 48.21% |
| Dec 31, 2021 | 280 | 101 | 56.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Autolus Therapeutics | 754 |
| CorMedix | 191 |
| Prime Medicine | 146 |
| Verastem | 102 |
| OmniAb | 89 |
| Scribe Therapeutics | 89 |
| Altimmune | 57 |
ARVN News
- 15 days ago - Arvinas price target lowered to $10 from $11 at Morgan Stanley - TheFly
- 15 days ago - Arvinas price target lowered to $14 from $19 at Evercore ISI - TheFly
- 15 days ago - Arvinas price target lowered to $21 from $24 at Citi - TheFly
- 20 days ago - Arvinas price target raised to $12 from $11 at Wedbush - TheFly
- 21 days ago - Wells downgrades Arvinas to Equal Weight, sees catalysts coming in 2027 - TheFly
- 21 days ago - Arvinas downgraded to Equal Weight from Overweight at Wells Fargo - TheFly
- 21 days ago - Arvinas reports Q2 EPS $2.58, consensus (28c) - TheFly
- 21 days ago - Arvinas Earnings Call Transcript: Q2 2026 - Transcripts